| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5701967 | Journal of Thoracic Oncology | 2017 | 34 Pages |
Abstract
In this prospective study, PRT for recurrent NSCLC is feasible but can be associated with significant toxicity. Providers should remain cautious in reirradiating NSCLC, paying close consideration to tumor volume, location, and relevant dosimetric parameters. Further research is needed for optimal patient selection to improve overall outcomes.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Hann-Hsiang MD, PhD, Abigail T. MD, MSCE, Charles B. MD, Christine MD, Peter MD, Haibo PhD, Stefan PhD, Corey MD, Kristi MS, Ramesh MD, PhD, Stephen M. MD, Kiran MD, Marcio MD, William MD, Rosemarie MS, John P. MD, PhD,